Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials

• Published in: Journal of clinical oncology Vol. 38; no. 28; pp. 3273 - 3281
• Main Authors: Noordhoek, Iris, Blok, Erik J, Meershoek-Klein Kranenbarg, Elma, Putter, Hein, Duijm-de Carpentier, Marjolijn, Rutgers, Emiel J T, Seynaeve, Caroline, Bartlett, John M S, Vannetzel, Jean-Michel, Rea, Daniel W, Hasenburg, Annette, Paridaens, Robert, Markopoulos, Christos J, Hozumi, Yasuo, Portielje, Johanneke E A, Kroep, Judith R, van de Velde, Cornelis J H, Liefers, Gerrit-Jan
• Format: Journal Article
• Language: English
• Published: United States 01.10.2020
• Subjects: Aged; Androstadienes - administration & dosage; Antineoplastic Agents, Hormonal - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Aromatase Inhibitors - administration & dosage; Breast Neoplasms - diagnosis; Breast Neoplasms - drug therapy; Breast Neoplasms - epidemiology; Breast Neoplasms - metabolism; Clinical Trials, Phase III as Topic; Cohort Studies; Female; Humans; Letrozole - administration & dosage; Middle Aged; Neoplasm Recurrence, Local - diagnosis; Neoplasm Recurrence, Local - epidemiology; Neoplasm Recurrence, Local - metabolism; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptors, Estrogen - metabolism; Reproducibility of Results; Risk Assessment - methods; Tamoxifen - administration & dosage

Most distant recurrences (DRs) in women with hormone receptor-positive breast cancer occur after 5 years from diagnosis. The Clinical Treatment Score post-5 years (CTS5) estimates DRs after 5 years of adjuvant endocrine therapy (AET). The aim of this study was to externally validate the CTS5 as a pr...